Cross-sectional and longitudinal validation of the Slovene version of the health-related quality of life questionnaire in patients with Hymenoptera venom allergy (HRQLH-S)

Abstract Background This study aimed to determine to what degree venom immunotherapy can affect the Quality of Life (QoL) in patients hypersensitive to the Hymenoptera venom and to validate the Slovene version of the “Vespid Allergy Quality of Life Questionnaire.” Methods The “Vespid Allergy Quality...

Full description

Saved in:
Bibliographic Details
Main Authors: T. Močnik, J. Šelb, M. Peršolja, M. Košnik
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Psychology
Subjects:
Online Access:https://doi.org/10.1186/s40359-025-02753-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850139332977885184
author T. Močnik
J. Šelb
M. Peršolja
M. Košnik
author_facet T. Močnik
J. Šelb
M. Peršolja
M. Košnik
author_sort T. Močnik
collection DOAJ
description Abstract Background This study aimed to determine to what degree venom immunotherapy can affect the Quality of Life (QoL) in patients hypersensitive to the Hymenoptera venom and to validate the Slovene version of the “Vespid Allergy Quality of Life Questionnaire.” Methods The “Vespid Allergy Quality of Life Questionnaire” (VQLQ), developed by Oude Elberink et al., has become a well-established diagnostic instrument. The Slovene version of the Health-Related Quality of Life Questionnaire for Hymenoptera venom allergy (HRQLH-S) was administered to 288 patients from different groups with a confirmed diagnosis of Hymenoptera venom hypersensitivity to achieve cross-sectional validation. The HRQLH-S results were compared among groups, with an Expectation of Outcome (EoO) questionnaire and a 10-point Likart scale question: (How much is your QoL reduced by being allergic to insect sting?). The questionnaire was administered to 49 patients treated with venom immunotherapy to establish longitudinal validity. Results In cross-sectional study, statistically significant differences (p < 0.001) were observed in patients treated with venom immunotherapy compared to untreated patients. The median (Mdn) was used to compare the groups. Patients that have already been treated recorded a rise in QoL only six months into treatment (Mdn = 3.18), compared to the untreated (Mdn = 4.20). Further noticeable improvements in the QoL were recorded in patients treated for three to five years (Mdn = 2.47). Statistically significant correlations between the HRQLH-S results and the EoO were confirmed in cases of patients with wasp venom hypersensitivity (Q15r = 0.82; Q16r = 0.67; Q17r = 0.63; p < 0.001) and those with honeybee venom hypersensitivity (Q15r = 0.79; Q16r = 0.62; Q17r = 0.64; p < 0.001). The cross-sectional validation yielded a correlation coefficient of 0.96 (Cronbach α). In the longitudinal validation, we showed a significant correlation between EoO and HRQLH-S (Q15r = 0.87; Q16r = 0.77; Q17r = 0.71; p < 0.000.1), with a good internal consistency (Cronbach α = 0.97). Furthermore, we found a significant difference (p < 0.001) in the QoL of pretreatment patients (Mdn = 3.91) compared to the value after five years of treatment (Mdn = 2.06). Conclusions Results confirm the efficiency of VIT on QoL in patients with Hymenoptera venom hypersensitivity. The HRQLH-S questionnaire proved suitable for measuring QoL in wasp and honeybee venom-allergic patients.
format Article
id doaj-art-8a68621c5b7e476e94ce1d0c3f9d1f7c
institution OA Journals
issn 2050-7283
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series BMC Psychology
spelling doaj-art-8a68621c5b7e476e94ce1d0c3f9d1f7c2025-08-20T02:30:19ZengBMCBMC Psychology2050-72832025-04-0113111010.1186/s40359-025-02753-6Cross-sectional and longitudinal validation of the Slovene version of the health-related quality of life questionnaire in patients with Hymenoptera venom allergy (HRQLH-S)T. Močnik0J. Šelb1M. Peršolja2M. Košnik3University Clinic of Respiratory and Allergic Diseases GolnikUniversity Clinic of Respiratory and Allergic Diseases GolnikUniversity of Primorska, Faculty of Health SciencesUniversity Clinic of Respiratory and Allergic Diseases GolnikAbstract Background This study aimed to determine to what degree venom immunotherapy can affect the Quality of Life (QoL) in patients hypersensitive to the Hymenoptera venom and to validate the Slovene version of the “Vespid Allergy Quality of Life Questionnaire.” Methods The “Vespid Allergy Quality of Life Questionnaire” (VQLQ), developed by Oude Elberink et al., has become a well-established diagnostic instrument. The Slovene version of the Health-Related Quality of Life Questionnaire for Hymenoptera venom allergy (HRQLH-S) was administered to 288 patients from different groups with a confirmed diagnosis of Hymenoptera venom hypersensitivity to achieve cross-sectional validation. The HRQLH-S results were compared among groups, with an Expectation of Outcome (EoO) questionnaire and a 10-point Likart scale question: (How much is your QoL reduced by being allergic to insect sting?). The questionnaire was administered to 49 patients treated with venom immunotherapy to establish longitudinal validity. Results In cross-sectional study, statistically significant differences (p < 0.001) were observed in patients treated with venom immunotherapy compared to untreated patients. The median (Mdn) was used to compare the groups. Patients that have already been treated recorded a rise in QoL only six months into treatment (Mdn = 3.18), compared to the untreated (Mdn = 4.20). Further noticeable improvements in the QoL were recorded in patients treated for three to five years (Mdn = 2.47). Statistically significant correlations between the HRQLH-S results and the EoO were confirmed in cases of patients with wasp venom hypersensitivity (Q15r = 0.82; Q16r = 0.67; Q17r = 0.63; p < 0.001) and those with honeybee venom hypersensitivity (Q15r = 0.79; Q16r = 0.62; Q17r = 0.64; p < 0.001). The cross-sectional validation yielded a correlation coefficient of 0.96 (Cronbach α). In the longitudinal validation, we showed a significant correlation between EoO and HRQLH-S (Q15r = 0.87; Q16r = 0.77; Q17r = 0.71; p < 0.000.1), with a good internal consistency (Cronbach α = 0.97). Furthermore, we found a significant difference (p < 0.001) in the QoL of pretreatment patients (Mdn = 3.91) compared to the value after five years of treatment (Mdn = 2.06). Conclusions Results confirm the efficiency of VIT on QoL in patients with Hymenoptera venom hypersensitivity. The HRQLH-S questionnaire proved suitable for measuring QoL in wasp and honeybee venom-allergic patients.https://doi.org/10.1186/s40359-025-02753-6Hymenoptera venom hypersensitivityVenom immunotherapyQuality of life
spellingShingle T. Močnik
J. Šelb
M. Peršolja
M. Košnik
Cross-sectional and longitudinal validation of the Slovene version of the health-related quality of life questionnaire in patients with Hymenoptera venom allergy (HRQLH-S)
BMC Psychology
Hymenoptera venom hypersensitivity
Venom immunotherapy
Quality of life
title Cross-sectional and longitudinal validation of the Slovene version of the health-related quality of life questionnaire in patients with Hymenoptera venom allergy (HRQLH-S)
title_full Cross-sectional and longitudinal validation of the Slovene version of the health-related quality of life questionnaire in patients with Hymenoptera venom allergy (HRQLH-S)
title_fullStr Cross-sectional and longitudinal validation of the Slovene version of the health-related quality of life questionnaire in patients with Hymenoptera venom allergy (HRQLH-S)
title_full_unstemmed Cross-sectional and longitudinal validation of the Slovene version of the health-related quality of life questionnaire in patients with Hymenoptera venom allergy (HRQLH-S)
title_short Cross-sectional and longitudinal validation of the Slovene version of the health-related quality of life questionnaire in patients with Hymenoptera venom allergy (HRQLH-S)
title_sort cross sectional and longitudinal validation of the slovene version of the health related quality of life questionnaire in patients with hymenoptera venom allergy hrqlh s
topic Hymenoptera venom hypersensitivity
Venom immunotherapy
Quality of life
url https://doi.org/10.1186/s40359-025-02753-6
work_keys_str_mv AT tmocnik crosssectionalandlongitudinalvalidationofthesloveneversionofthehealthrelatedqualityoflifequestionnaireinpatientswithhymenopteravenomallergyhrqlhs
AT jselb crosssectionalandlongitudinalvalidationofthesloveneversionofthehealthrelatedqualityoflifequestionnaireinpatientswithhymenopteravenomallergyhrqlhs
AT mpersolja crosssectionalandlongitudinalvalidationofthesloveneversionofthehealthrelatedqualityoflifequestionnaireinpatientswithhymenopteravenomallergyhrqlhs
AT mkosnik crosssectionalandlongitudinalvalidationofthesloveneversionofthehealthrelatedqualityoflifequestionnaireinpatientswithhymenopteravenomallergyhrqlhs